Hey Daniel, @Mason14,
Have either of you come across this specific m6a x cardiovascular failure study?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263194/
Mason, I know you’ve worked through and posted a lot on the contrary primary mechanism of FTO inhib x chemo cardio toxic and the secondary cardioprotective mechanism of bisantrene (prefacing M1M), so this article’s commentary on how increased FTO/changes in other m6a agents helps cardiac health markers (i.e improved Ca2+ homeostasis) might be of interest/relevance.
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-139
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
-0.075(4.00%) |
Mkt cap ! $315.1M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.88 | $1.80 | $84.44K | 46.06K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 9148 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 622 | 2 |
View Market Depth
| Last trade - 11.57am 18/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |